Live Oak Investment Partners Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Live Oak Investment Partners increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 551.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,601 shares of the company's stock after acquiring an additional 7,281 shares during the period. Johnson & Johnson comprises approximately 1.1% of Live Oak Investment Partners' holdings, making the stock its 24th largest position. Live Oak Investment Partners' holdings in Johnson & Johnson were worth $1,426,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the 4th quarter worth about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $38,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.0%

NYSE JNJ opened at $152.25 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $366.33 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The stock's 50-day moving average price is $153.85 and its 200-day moving average price is $153.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.42%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.